A Study to Assess the Efficacy and Safety of XC221 in Patients With COVID-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

118 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-07-25

Study Completion Date

2020-10-29

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The innovative drug XC221 100 mg tablet is designed for the treatment of COVID-19 (SARS-CoV-2 infection). A multicenter, adaptive, randomized, double-blind, placebo-controlled Phase III clinical study is aimed to assess the efficacy and safety of XC221 100 mg tablet, in COVID-19 patients during a 14-day treatment.

The primary objective of the study is to demonstrate the efficacy of XC221 100 mg tablet (200 mg daily dose) in achieving clinical improvement of COVID-19 symptoms.

The secondary objective of the study is to evaluate the safety of XC221 100 mg tablet (200 mg daily dose) in COVID-19 patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study to Assess Efficacy and Safety of XC221 in the Treatment of Influenza and Other Acute Respiratory Viral Infections

NCT03455491

Acute Respiratory Viral Infections Influenza

COMPLETED PHASE2

Study to Assess Efficacy and Safety of XC221 200 mg in the Treatment of Influenza or Other ARVI

NCT03830905

Influenza Acute Respiratory Viral Infections

COMPLETED PHASE2

A Study to Evaluate the Safety and Efficacy of XC221 in Patients With Uncomplicated Influenza or Other Acute Viral Upper Respiratory Infections

NCT05544916

Influenza Respiratory Viral Infection

COMPLETED PHASE3

A Study to Evaluate the Safety, Tolerability and Efficacy of XC221 in Patients With Uncomplicated Influenza or Other Acute Viral Upper Respiratory Infections

NCT05030324

Influenza Viral Respiratory Infection Acute Viral Upper Respiratory Infections

COMPLETED PHASE2

Study to Assess Safety, Tolerability and Pharmacokinetics of XC221 in Healthy Volunteers

NCT03459391

Influenza Acute Respiratory Infection

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

11 Russian centers will participate in this study. The trail will consist of three periods: screening (duration not more than 1 day, it may coincide with the randomization visit and beginning of drug administration), treatment period (14 days) and follow-up period (14 ± 1 days after completion of treatment with XC221 / Placebo). The duration of participation in the study for each patient will be no more than 30 days.

118 eligible patients with confirmed COVID-19 will be randomized into two groups (Group A and Group B) in a 1:1 ratio: Group A - XC221 200 mg daily (59 patients); Group В - Placebo (59 patients).

During the treatment period (14 days), 1 tablet of XC221 / Placebo will be administered 2 times a day in addition to the standard of care (SoC) for COVID-19 according to The Temporary guidelines for the prevention, diagnosis and treatment of SARS-CoV-2 infection of the Ministry of Health of the Russian Federation (the MoH Temporary Guidelines). The follow-up period will last for 14 days.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

SARS-CoV-2 Infection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Tablets identical in terms of composition, appearance and labeling to XC221 tablets, but without active substance will be used as Placebo.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

XC221

XC221 100 mg orally.

1 tablet of XC221 100 mg 2 times a day during 14 days of treatment period.

Group Type EXPERIMENTAL

XC221

Intervention Type DRUG

Participants will receive XC221 100 mg 2 times a day during 14 days

Placebo

Placebo orally.

1 tablet of Placebo 2 times a day during 14 days of treatment period

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Participants will receive Placebo 2 times a day during 14 days

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

XC221

Participants will receive XC221 100 mg 2 times a day during 14 days

Intervention Type DRUG

Placebo

Participants will receive Placebo 2 times a day during 14 days

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Signed Informed Consent Form.
2. Patients of both sexes aged 18 to 75 years inclusive.
3. Diagnosed COVID-19 based on:

* positive laboratory tests confirming the SARS-CoV-2 presence, performed no earlier than 14 days before hospitalization. It is allowed to determine the SARS-CoV-2 by the PCR or by another method according to the MoH Temporary Guidelines; and / or
* bilateral alterations in lungs, typical for COVID-19, according to CT scan of the chest.
4. Patients with moderate or severe form of disease (t \> 38.0°C; respiratory rate (RR) \>22 / min; Sp02 \<95%) not requiring non-invasive / invasive ventilation and / or high-flow oxygenation (HFNT), and / or extracorporeal membrane oxygenation (EMO) at the time of screening and randomization (based on the MoH Temporary Guidelines).
5. Patients requiring oxygen therapy (oxygenation through a nasal cannula, a simple facemask or other similar oxygen delivery device) with a category "4" according to the WHO scale.

Exclusion Criteria

7. Disease duration is no more than 7 full days since the moment of appearing one or more of the symptoms below until the first dose of the drug administration:

* temperature increase;
* dry cough or cough with little phlegm;
* shortness of breath;
* myalgia;
* fatigue;
* feeling of congestion in the chest;
* reduced sense of smell and / or taste.
8. For women only: negative pregnancy test result. Pregnancy testing is not required for women of not childbearing potential (WONCBP): women who are in menopause (defined as an absence of menstruation for at least 2 years or more), or women who undergone surgical sterilization (hysterectomy, bilateral oophorectomy, tubal ligation), or women with a clinical diagnosis of "infertility". The presence of surgical sterilization and infertility should be confirmed by patient's claim or by relevant document confirming this condition.
9. Consent to use reliable method of contraception throughout the study period.
10. Patients who are able to understand and comply with treatment and procedures during the study.

1. Known or suspected hypersensitivity to the active substance or to excipients of the drug XC221 or placebo
2. Known or suspected hypersensitivity to standard therapy drugs specified in The MoH Temporary Guidelines.
3. Lactase deficiency, lactose intolerance, glucose-galactose malabsorption.
4. Presence or suspicion of oncological diseases by the day of criteria assessment or in medical history (within the last 2 years).
5. Presence of autoimmune diseases by the day of criteria assessment or in medical history.
6. Neutropenia (0.5 \* 10\^9 /l).
7. Exceeding the upper limit of normal for ALT and AST by 5 times or more.
8. Thrombocytopenia 50000 / mm\^3.
9. Pregnancy.
10. Lactation.
11. Presence of serious lung diseases, including, but not limited to the following diseases: moderate and severe bronchial asthma, severe and extremely severe COPD, interstitial lung disease, pulmonary hypertension, pulmonary fibrosis, surgical interventions on the lungs, tuberculosis (including suspicion of tuberculosis based on the results of CT examination at screening).
12. Patients with type 1 diabetes mellitus and / or decompensated type 2 diabetes mellitus.
13. Heart failure, NYHA functional class III - IV.
14. Chronic liver failure stage II (decompensated) and higher.
15. The need of renal replacement therapy at the time of inclusion of the patient.
16. Organ transplantation in medical history.
17. Medical history of epilepsy or the need for anticonvulsant therapy.
18. Major depressive disorder, anxiety, other mental disorders requiring medical correction.
19. Acute cerebrovascular accident, stroke or transient ischemic attack within 90 days before screening.
20. Administration of any antiviral and / or immunomodulatory drugs after the manifestation of COVID-19, with the exception of those specified in the MoH Temporary Guidelines.
21. Any immunosuppressive therapy (including tocilizumab / sarilumab) within 90 days prior to randomization, or the need of immunosuppressive therapy at the time of randomization.
22. Administration of systemic glucocorticosteroids within 90 days prior to randomization, or the need of systemic glucocorticosteroids at the time of randomization.
23. Administration of vaccines against viral infections within 90 days prior to randomization.
24. Patients receiving other experimental drugs, drugs not approved in the Russian Federation, or participating in other clinical trials within 30 days before screening.
25. Patients abusing alcohol or psychotropic drugs and other drugs by the day of criteria assessment or during the last year.
26. Patients with other serious, unstable, or clinically significant medical or psychological conditions that, in the opinion of the investigator, may preclude the patient's participation in the study.
27. Expected death within 48 hours after randomization.
28. Expected hospital discharge within 48 hours of randomization.

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No